Keys to personalized care in pancreatic oncology

Journal of Clinical Oncology

Volumn 30, Issue 33, 2012, Pages 4049-4050

  Crane, Christopher H ^a   Iacobuzio Donahue, Christine A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; BRCA2 PROTEIN; CISPLATIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; GEMCITABINE; INTERFERON RECEPTOR; OSTEONECTIN; SMAD4 PROTEIN;

CANCER CENTER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHEMORADIOTHERAPY; CHILD; CHILD HOSPITALIZATION; CHILDHOOD CANCER; CLINICAL DECISION MAKING; EDITORIAL; ENDOSCOPIC BIOPSY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; GENE DELETION; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL THERAPY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS METASTASIS; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; STATISTICAL SIGNIFICANCE; STOMACH OBSTRUCTION; TRANSLATIONAL RESEARCH; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84869456305     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.1799     Document Type: Editorial

References (12)

1. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185:476-480, 2003
2. Katz MH, Wolff R, Crane CH, et al: Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: A phase II trial. Ann Surg Oncol 18:3615-3622, 2011
3. Linehan DC, Tan MC, Strasberg SM, et al: Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: A single-institution phase II study. Ann Surg 248:145-151, 2008
4. Picozzi VJ, Abrams RA, Decker PA, et al: Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 22:348-354, 2011
5. Schmidt J, Abel U, Debus J, et al: Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 30:4077-4083, 2012
6. Reference deleted
7. Saidi RF, Remine SG, Jacobs MJ: Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer. HPB (Oxford) 9:289-294, 2007
8. Saidi RF, Jacobs MJ: Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma. Ann Surg 249:865-866, 2009
9. Farrell JJ, Elsaleh H, Garcia M, et al: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187-195, 2009
10. Bhutani MS: The year of improved tissue acquisition, randomized trials, and endoscopic ultrasound-guided therapy. Endoscopy 43:993-999, 2011
11. Iacobuzio-Donahue CA, Fu B, Yachida S, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813, 2009
12. Crane CH, Varadhachary GR, Yordy JS, et al: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29:3037-3043, 2011